Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Mkilloran who wrote (11093)	7/10/1998 1:12:00 AM
From: VLAD	Read Replies (1) \| Respond to of 23519

1)Alibra is Vivus's next product that is in phase III clinical trials. It is a combination of aloprostidal and another drug which is a vasodialator. The second drug lowers the amount of aloprostidal needed thus achieving less pain and it is more effective. It nworked in 25% of cases that did not respond to MUSE alone. 2)Incontinence is where an individual can not control their urination thus pissing in their pants. The market in this is way bigger than the ED market. If they do get something approved then I suggest shorting the company that makes Depends. 3)Nothing. But Vivus's most promising next generation ED cure is an injection that is given but once every 2 months. It sounds promising.